Proteome Sciences logo

PRM - Proteome Sciences Share Price

3.74p -0.2  -4.1%

Last Trade - 9:52am

Sector
Healthcare
Size
Micro Cap
Market Cap £11.5m
Enterprise Value £21.0m
Revenue £4.82m
Position in Universe 1552nd / 1809
Bullish
Bearish
Unlock PRM Revenue
Momentum
Relative Strength (%)
1m +0.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1.56 1.88 2.74 3.38 3.05 4.66 +24.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, ProteomeSciences plc revenues increased 9% to £1.9M. Net lossincreased 21% to £514K. Revenues reflect Grant servicesincrease of 93% to £27K. Higher net loss reflectsAdministrative expenses increase of 14% to £1.4M (expense),Finance costs increase of 4% to £168K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PRM Revenue Unlock PRM Revenue

Net Income

PRM Net Income Unlock PRM Revenue

Normalised EPS

PRM Normalised EPS Unlock PRM Revenue

PE Ratio Range

PRM PE Ratio Range Unlock PRM Revenue

Dividend Yield Range

PRM Dividend Yield Range Unlock PRM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PRM EPS Forecasts Unlock PRM Revenue
Profile Summary

Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It operates through the EU (the United Kingdom and Germany) and the United States geographic regions. Through the United Kingdom segment, it provides protein separation and MS capabilities for identification and analysis of post-translational modification of proteins in protein phosphorylation, image analysis and bioinformatics. Through the Germany segment, it provides protein profiling technologies, such as Tandem Mass Tags (TMT), which offers quantitation of proteins for the discovery of biomarkers. It has research agreements with various institutions in the United States.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated December 10, 1993
Public Since October 3, 1995
No. of Shareholders: n/a
No. of Employees: 25
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 295,182,056
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PRM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PRM
Upcoming Events for PRM
Frequently Asked Questions for Proteome Sciences
What is the Proteome Sciences share price?

As of 9:52am, shares in Proteome Sciences are trading at 3.74p, giving the company a market capitalisation of £11.5m. This share price information is delayed by 15 minutes.

How has the Proteome Sciences share price performed this year?

Shares in Proteome Sciences are currently trading at 3.74p and the price has moved by 20% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Proteome Sciences price has moved by 13.95% over the past year.

What are the analyst and broker recommendations for Proteome Sciences?

Of the analysts with advisory recommendations for Proteome Sciences, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Proteome Sciences is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Proteome Sciences next release its financial results?

Proteome Sciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Proteome Sciences dividend yield?

Proteome Sciences does not currently pay a dividend.

Does Proteome Sciences pay a dividend?

Proteome Sciences does not currently pay a dividend.

When does Proteome Sciences next pay dividends?

Proteome Sciences does not currently pay a dividend.

How do I buy Proteome Sciences shares?

To buy shares in Proteome Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Proteome Sciences?

Shares in Proteome Sciences are currently trading at 3.74p, giving the company a market capitalisation of £11.5m.

Where are Proteome Sciences shares listed? Where are Proteome Sciences shares listed?

Here are the trading details for Proteome Sciences:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: PRM
What kind of share is Proteome Sciences?

Based on an overall assessment of its quality, value and momentum, Proteome Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Proteome Sciences share price forecast 2021?

Shares in Proteome Sciences are currently priced at 3.74p. At that level they are trading at 53.85% discount to the analyst consensus target price of 8.10.

How can I tell whether the Proteome Sciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proteome Sciences. Over the past six months, the relative strength of its shares against the market has been -6.28%. At the current price of 3.74p, shares in Proteome Sciences are trading at 2.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Proteome Sciences PE Ratio?

The Proteome Sciences PE ratio based on its reported earnings over the past 12 months is 0.186k. The shares are currently trading at 3.74p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Proteome Sciences?

Proteome Sciences's management team is headed by:

Christopher Pearce - CHM
Ian Pike - CSO
Glenn Barney - VBD
Malcolm Ward - CTO
Josef Schwarz - OTH
Roger McDowell - NED
Gee See Chee - DRC
Geoffrey Ellis - FID
Martin Diggle - NED
Richard Dennis - OTH
Ursula Ney - NED
Mariola Sohngen - CEO
Who are the major shareholders of Proteome Sciences?

Here are the top five shareholders of Proteome Sciences based on the size of their shareholding:

Vulpes Investment Management Private Limited Hedge Fund
Percentage owned: 22.3% (65.8m shares)
Pearce (Christopher Donovan James) Individual Investor
Percentage owned: 12.51% (36.9m shares)
ISPartners Investment Solutions AG Hedge Fund
Percentage owned: 4.79% (14.2m shares)
Spreadex, Ltd. Corporation
Percentage owned: 1.98% (5.86m shares)
Walraven (Albert Johan) Individual Investor
Percentage owned: 0.89% (2.64m shares)
Similar to PRM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.